The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.

摘要: Purpose To compare the safety and intraocular pressure (IOP)-lowering efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution (Trav/Tim) to its components 0.004% solution, TRAVATAN, (Trav) timolol (Tim) in patients with open-angle glaucoma or ocular hypertension. Design Randomized multicenter, double-masked, active-controlled, parallel group study. Methods Two hundred sixty-three hypertension were randomized receive Trav/Tim once daily AM (and vehicle PM), Trav PM AM), Tim twice (AM PM). Efficacy compared across treatment groups over 3 months. Results produced a mean IOP decrease from baseline 1.9 mm Hg 3.3 more than Tim, significant at each nine study visits ( P ≤ .003). decreased by 0.9 2.4 Trav, seven .05). The adverse event profile for was comparable alone. Conclusions Over months treatment, clinically relevant reductions that greater those either clinical results safe well tolerated an incidence events provides both effective reduction benefits once-daily dosing.